Yahoo · Sep 3, 2026
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.
AC
NASDAQ · ACIU
AC Immune S.A.
Healthcare · Biotechnology
$2.68
Down-$0.03 (-1.12%)
Updated Sep 16, 2026, 8:02 PM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 294.76M
- P/E ratio
- -3.11
- Dividend yield
- 0.00%
- 52-week range
- $2.10 – $3.49
- Volume
- 93.53K
- Avg. volume
- 714.24K
Price performance
ACIU price history
1M range · 20 trading sessions · Daily adjusted prices
ACIU closed at $2.68 after 20 trading sessions, up 4.28% for the selected period.
- Last close
- $2.68
- Period change
- +4.28%
- Period low
- $2.57
- Period high
- $2.93
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $2.65 | $2.70 | $2.59 | $2.68 | 93.53K |
| Sep 14, 2026 | $2.69 | $2.75 | $2.66 | $2.66 | 111.83K |
| Sep 11, 2026 | $2.70 | $2.775 | $2.68 | $2.76 | 105.37K |
| Sep 10, 2026 | $2.74 | $2.77 | $2.68 | $2.69 | 157.53K |
| Sep 9, 2026 | $2.78 | $2.81 | $2.725 | $2.76 | 146.57K |
| Sep 8, 2026 | $2.82 | $2.85 | $2.77 | $2.78 | 100.87K |
| Sep 4, 2026 | $2.91 | $2.94 | $2.82 | $2.86 | 155.63K |
| Sep 3, 2026 | $2.85 | $3.00 | $2.85 | $2.93 | 171.77K |
| Sep 2, 2026 | $2.70 | $2.865 | $2.70 | $2.84 | 257.18K |
| Sep 1, 2026 | $2.62 | $2.68 | $2.58 | $2.68 | 103.47K |
| Aug 31, 2026 | $2.67 | $2.735 | $2.61 | $2.64 | 132.96K |
| Aug 28, 2026 | $2.73 | $2.77 | $2.65 | $2.65 | 105.71K |
| Aug 27, 2026 | $2.83 | $2.91 | $2.685 | $2.71 | 169.43K |
| Aug 26, 2026 | $2.94 | $2.98 | $2.77 | $2.85 | 269.06K |
| Aug 25, 2026 | $2.85 | $2.965 | $2.85 | $2.92 | 241.3K |
| Aug 24, 2026 | $2.91 | $3.00 | $2.7986 | $2.86 | 371.17K |
| Aug 21, 2026 | $2.66 | $2.945 | $2.65 | $2.90 | 442.01K |
| Aug 20, 2026 | $2.60 | $2.65 | $2.435 | $2.64 | 237.11K |
| Aug 19, 2026 | $2.60 | $2.69 | $2.565 | $2.58 | 280.71K |
| Aug 18, 2026 | $2.54 | $2.59 | $2.505 | $2.57 | 90.23K |
Latest ACIU news
The latest Smart Investors Daily articles mentioning ACIU.
Stock researchCompany · Overview
ACIU research
Overview
Company profile and research snapshot.
Company profile
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.00
- Implied upside
- —
- Analysts
- 9
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | BTIG | Buy | — |
| Aug 5, 2026 | BTIG | Buy | — |
| May 4, 2026 | BTIG | Buy | — |
| Mar 16, 2026 | BTIG | Buy | — |
| Nov 4, 2025 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.
Yahoo · Sep 1, 2026
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.
Yahoo · Aug 31, 2026
LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
